<DOC>
	<DOCNO>NCT02185053</DOCNO>
	<brief_summary>This Phase II , Single-Blind , Placebo-Controlled , Sequential Treatment , Multiple Ascending Dose Study Evaluate Safety Tolerability CPC-201 Patients Alzheimer 's Disease Type Dementia .</brief_summary>
	<brief_title>A Phase II Study CPC-201 Treat Alzheimer 's Disease Type Dementia</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Aged 50 79 year inclusive . Meeting diagnosis probable Alzheimer 's Disease Of moderate severity ( MiniMental Status Exam [ MMSE ] score 10 20 inclusive ) . Patients must generally good health indicate medical history physical examination , vital sign , electrocardiogram ( ECG ) , standard laboratory test . Women child bear potential . History presence seizure disorder . History peptic ulcer disease , urinary gastric retention ; asthma obstructive pulmonary disease . History presence bladder outflow obstruction , gastrointestinal obstructive disorder reduce GI motility , narrowangle glaucoma . History presence gastrointestinal , hepatic , renal disease , condition know interfere absorption , distribution , metabolism excretion drug . History presence myasthenia . Known hypersensitivity donepezil , solifenacin related drug . Any clinically relevant acute chronic disease could interfere patient ' safety trial , expose undue risk , could interfere study objective . Patients participate another clinical trial investigational drug within previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>